CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. Our lead drug, Berubicin, is an exciting discovery for the treatment of Glioblastoma Multiforme (GBM) and potentially for other CNS malignancies. Berubicin was first discovered at the MD Anderson Cancer Center, one of the largest cancer institutes in the world. CNS has obtained a worldwide exclusive license to the Berubicin patent from Houston Pharmaceuticals, the original commercial holder of the Berubicin intellectual property. CNS has also acquired all data and know-how related to the Phase 1 trial of Berubicin from Reata Pharmaceuticals, a multibillion dollar NASDAQ listed company. In 2017, CNS entered into a collaboration agreement with Reata to further advance the development of Berubicin. In 2019, with the funding secured from our NASDAQ IPO, CNS will commence its Phase 2(a) clinical trial of Berubicin for the treatment of GBM. CNS may also pursue the development of Berubicin to treat additional diseases, including pancreatic and ovarian cancers and lymphoma. CNS may also develop combination therapies that include Berubicin.
No articles found.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (â...
Lantheus Holdings, Inc. is the parent company o...
iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solut...
iCAD, Inc. an industry-leading provider of adva...
Founded by a group of pioneers in cannabis research and industry development, and ...
Founded by a group of pioneers in cannabis rese...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our ...
Since our foundation in Dublin, Ireland in 1990...
ARCA was founded on the belief that a precision medicine approach to drug developm...
ARCA was founded on the belief that a precision...
Athenex is a global oncology focused biopharmaceutical company dedicated to the di...
Athenex is a global oncology focused biopharmac...
Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a...
Oramed Pharmaceuticals (NASDAQ: ORMP) was estab...
Join the National Investor Network and get the latest information with your interests in mind.